Mahnke has completed multiple successful investigational new drug applications and brings deep expertise in pharmaceutical development to Bicycle, including experience in clinical development, clinical pharmacology and translational medicine.
West is a seasoned biopharma executive with experience across multiple therapeutic areas and project functions.
Lisa Mahnke will lead Bicycle's clinical efforts. Most recently, Dr. Mahnke was head of clinical development at Dragonfly Therapeutics and Syros Pharmaceuticals.
Before that, she held positions of increasing responsibility in clinical pharmacology and clinical development, including medical lead and head of clinical pharmacology, at BMS, Merck, EMD Serono and Vertex Pharmaceuticals.
She is a licensed and prior board-certified physician in internal medicine and infectious diseases. Dr. Mahnke holds a B.S. in chemistry from Ripon College, a Ph.D. in biochemistry and an M.D. from the University of Wisconsin-Madison.
Terrence West was most recently Executive director, Project Management, at EMD Serono, where he successfully led multiple teams from discovery through initial FDA filings, including Phase I-III clinical program approvals and launches.
He has also worked in program management for companies including ZioPharm Oncology, Stryker Regenerative Medicine, Dynavax Technologies and Exelixis, Inc. West holds a B.S. in chemistry from the University of Arizona and an MBA in Technology Management from the University of Phoenix.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops that stabilize their structural geometry.
This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial